Validcare Announces a Second Cohort of CBD Brands Joins Safety Study to Gather Data for FDA
Share Article
Validcare s Decentralized Clinical Trial Allows for Consumer Participation During COVID We are excited to have our state of the art, decentralized trial technology overcome the hurdles of performing research during a pandemic. DENVER (PRWEB) April 15, 2021 Validcare announced today the addition of a second cohort of CBD brands participating in a large scale, human safety study, a significant and widescale endeavor to answer the FDA’s call for additional safety data. This second cohort expands the reliability of Validcare’s recently completed findings in Cohort 1 regarding liver safety in healthy adults ingesting either full or broad-spectrum hemp-derived CBD. The study is designed to respond to the FDA’s repeated requests, including the Agency’s March 5, 2020 report to Congress for science-based da
Study: No evidence of liver toxicity from use of CBD from hemp
Investigators report to FDA no evidence of liver toxicity in 839 adults consuming oral CBD
Published:
Updated:
Tags:
CBD products
Researchers presented initial results from a study to the FDA in March suggesting there is no evidence of liver disease from the use of hemp-derived CBD products.
The study, conducted by a team from clinical research company Validcare, aims to help the FDA to determine how to appropriately regulate CBD products.
CBD, short for cannabidiol, comes from the cannabis plant. It is one of two most commonly known compounds of cannabis (marijuana), the other being delta-9-tetrahydrocannabinol (THC). It’s the THC that is associated with a “high,” not CBD.
Validcare s Clinical Study Reports Preliminary Results of CBD Liver Safety prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.